Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106807 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne
A Phase 2 study of Acne, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 9
- Study locations
NCT01106807: Completed Phase 2 study of Acne, sponsored by Galderma R&D.
NCT01106807 is a Phase 2 study of Acne that has completed, run by Galderma R&D. The registered enrollment target is 73 participants, below the 140-participant average among 26 other Acne trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01106807, a Phase 2 study of Acne, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice daily applications. The study will also evaluate the safety of the study products using tolerance and adverse event data.
Primary Outcome
change in total number of acne lesion count from baseline to end of treatment
Conditions Studied
Interventions
- DRUG Epiduo vehicle gel
- DRUG CD07223
- DRUG Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Study Locations (9)
Texas
- Derm Research, Inc - Austin
- J & S Studies - Bryan
Arkansas
- Burke Pharmaceuticals - Hot Springs
Kentucky
- Dermatology Specialist PSC - Louisville
Michigan
- Grekin Skin Institute - Warren
New Jersey
- TKL Research - Rochelle Park
North Carolina
- Piedmont Medical Research - Winston-Salem
North Dakota
- Cetero - Fargo
Virginia
- Education and Research Foundation, Inc - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT01106807 record still lists
NCT01106807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 140-participant average among 26 other Acne trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 3 interventions - of which Epiduo vehicle gel is the first listed.
NCT01106807 lists 9 locations in 8 states (Texas, Arkansas, Kentucky).
Frequently Asked Questions
What is clinical trial NCT01106807 about?
NCT01106807 is a clinical study titled "Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne". The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice daily applications. The study will also evaluate the safety of the study products using tolerance and adverse event da...
What is the current status of trial NCT01106807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2010-04. Estimated completion is 2010-09.
What conditions does trial NCT01106807 study?
This clinical trial studies the following conditions: Acne.
What interventions are being tested in trial NCT01106807?
The interventions under investigation include: Epiduo vehicle gel (DRUG), CD07223 (DRUG), Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel (DRUG).
Who is sponsoring clinical trial NCT01106807?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01106807 being conducted?
This trial has 9 study locations across Arkansas, Kentucky, Michigan, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01106807's enrollment target sits among peer trials
73 13th of 26 higher than 14 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
RECRUITING · Phase 1
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
RECRUITING · Phase 1
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
RECRUITING · Phase 1
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia